Kyverna Therapeutics, Inc.
KYTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeKyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company carries a $333.3M market cap, placing it firmly in the small-cap category. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Market Cap
$333.3M
Beta
2.06
P/E (TTM)
—
P/E (Fwd)
-1.70
EPS (TTM)
$-2.93
EPS (Fwd)
$-3.17
ROE
-87.2%
ROA
-44.5%
Cash
$199.4M
Total Debt
$33.0M
Free CF
-$107.7M
52W Change
-31.0%
Annual Financials
Cash vs Debt
Where KYTX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, KYTX finished 30.68% below its 150-day moving average ($8.18) and 31.11% below its 200-day moving average ($8.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYTX overbought or oversold?
At the October 19, 2026 close, KYTX's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kyverna Therapeutics, Inc. holds $199.4M in cash against $33.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$107.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -87.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.7M (2021) to $0 (2025), a 100% decline worth watching.
Kyverna Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, KYTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KYTX.